All Stories

  1. Inhalable dry powder containing remdesivir and disulfiram: Preparation and in vitro characterization
  2. Spray-Dried Inhalable Microparticles Combining Remdesivir and Ebselen against SARS-CoV-2 Infection
  3. Directed Evolution of Seneca Valley Virus in Tumorsphere and Monolayer Cell Cultures of a Small-Cell Lung Cancer Model
  4. Manipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder
  5. Characterization of the First SARS-CoV-2 Isolates from Aotearoa New Zealand as Part of a Rapid Response to the COVID-19 Pandemic
  6. Chikungunya Virus’ High Genomic Plasticity Enables Rapid Adaptation to Restrictive A549 Cells
  7. Ultraviolet-C Irradiation, Heat, and Storage as Potential Methods of Inactivating SARS-CoV-2 and Bacterial Pathogens on Filtering Facepiece Respirators
  8. Rapid Response to SARS-CoV-2 in Aotearoa New Zealand: Implementation of a Diagnostic Test and Characterization of the First COVID-19 Cases in the South Island
  9. Chronic opioid use modulates human enteric microbiota and intestinal barrier integrity
  10. Tenth Scientific Biennial Meeting of the Australasian Virology Society—AVS10 2019
  11. Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy
  12. Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing
  13. HIV/AIDS in Sierra Leone: Characterizing the Hidden Epidemic
  14. First-line HIV treatment failures in non-B subtypes and recombinants: a cross-sectional analysis of multiple populations in Uganda
  15. Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay
  16. Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda
  17. Emergence of Resistance to Colistin During the Treatment of Bloodstream Infection Caused by Klebsiella pneumoniae Carbapenemase–Producing Klebsiella pneumoniae
  18. Tapering Courses of Oral Vancomycin Induce Persistent Disruption of the Microbiota That Provide Colonization Resistance to Clostridium difficile and Vancomycin-Resistant Enterococci in Mice
  19. Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries
  20. Prion seeding activity and infectivity in skin samples from patients with sporadic Creutzfeldt-Jakob disease
  21. HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters
  22. Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals
  23. Increased replication capacity following evolution of PYxE insertion in Gag-p6 is associated with enhanced virulence in HIV-1 subtype C from East Africa
  24. Novel high throughput pooled shRNA screening identifies NQO1 as a potential drug target for host directed therapy for tuberculosis
  25. Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure
  26. Identifying Variants in GBM: Comparison of ExomeSeq and CCP
  27. Deep sequencing: Becoming a critical tool in clinical virology
  28. Role of HIV Minority Variants in Drug Resistance
  29. HIV-1 and GBV-C co-infection in Venezuela
  30. Next-Generation Sequencing to Help Monitor Patients Infected with HIV: Ready for Clinical Use?
  31. Sensitive Deep-Sequencing-Based HIV-1 Genotyping Assay To Simultaneously Determine Susceptibility to Protease, Reverse Transcriptase, Integrase, and Maturation Inhibitors, as Well as HIV-1 Coreceptor Tropism
  32. Impact of Resistance Mutations on HIV-1 Replicative Fitness and INSTI Susceptibility
  33. Sensitive Cell-Based Assay for Determination of Human Immunodeficiency Virus Type 1 Coreceptor Tropism
  34. Comparison of Four NGS Platforms for HIV-1 Coreceptor Tropism Prediction
  35. Editorial: [Hot Topic: Use of Microbicides to Prevent HIV Sexual Transmission (Guest Editor: Miguel E. Quinones-Mateu)]
  36. Mucosal Transmission of Human Immunodeficiency Virus
  37. Virus-inhibitory peptide
  38. Identification of low-molecular weight inhibitors of HIV-1 reverse transcriptase using a cell-based high-throughput screening system
  39. Human Immunodeficiency Virus Type 1 Resistance or Cross-Resistance to Nonnucleoside Reverse Transcriptase Inhibitors Currently under Development as Microbicides
  40. Novel Method for Simultaneous Quantification of Phenotypic Resistance to Maturation, Protease, Reverse Transcriptase, and Integrase HIV Inhibitors Based on 3′Gag(p2/p7/p1/p6)/PR/RT/INT-Recombinant Viruses: a Useful Tool in the Multitarget Era of Antire...
  41. Human Immunodeficiency Virus Type 1 Resistance or Cross-Resistance to Nonnucleoside Reverse Transcriptase Inhibitors Currently under Development as Microbicides
  42. Novel Recombinant Virus Assay for Measuring Susceptibility of Human Immunodeficiency Virus Type 1 Group M Subtypes To Clinically Approved Drugs
  43. Current tests to evaluate HIV-1 coreceptor tropism
  44. Increased Levels of Human Beta-Defensins mRNA in Sexually HIV-1 Exposed But Uninfected Individuals
  45. Impact on Replicative Fitness of the G48E Substitution in the Protease of HIV-1
  46. Viral Drug Resistance and Fitness
  47. Viral fitness: relation to drug resistance mutations and mechanisms involved: nucleoside reverse transcriptase inhibitor mutations
  48. The impact of viral and host elements on HIV fitness and disease progression
  49. Cystic Fibrosis and Normal Human Airway Epithelial Cell Response to Influenza A Viral Infection.
  50. Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness
  51. HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors
  52. Role of Human β-defensins in HIV Infection
  53. Virus Fitness: Concept, Quantification, and Application to HIV Population Dynamics
  54. Persistent Replication of Human Immunodeficiency Virus Type 1 despite Treatment of Pulmonary Tuberculosis in Dually Infected Subjects
  55. Is HIV-1 evolving to a less virulent (pathogenic) virus?
  56. The Replicative Fitness of Primary Human Immunodeficiency Virus Type 1 (HIV-1) Group M, HIV-1 Group O, and HIV-2 Isolates
  57. Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection
  58. Diminished Replicative Fitness of Primary Human Immunodeficiency Virus Type 1 Isolates Harboring the K65R Mutation
  59. HIV-1 mutagenesis during antiretroviral therapy: implications for successful drug treatment
  60. Drug Resistance, Virus Fitness and HIV-1 Mutagenesis
  61. Failure to Detect Human Immunodeficiency Virus Type 1 Superinfection in 28 HIV-Seroconcordant Individuals with High Risk of Reexposure to the Virus
  62. Fitness Variations and their Impact on the Evolution of Antiretroviral Drug Resistance
  63. Human epithelial β-defensins 2 and 3 inhibit HIV-1 replication
  64. Role of the Human Immunodeficiency Virus Type 1 Envelope Gene in Viral Fitness
  65. A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy
  66. Role of Baseline pol Genotype in HIV-1 Fitness Evolution
  67. Sorting out the complexities of HIV-1 fitness
  68. Comparing the Ex Vivo Fitness of CCR5-Tropic Human Immunodeficiency Virus Type 1 Isolates of Subtypes B and C
  69. Fitness of drug resistant HIV-1: methodology and clinical implications
  70. Insertions in the Reverse Transcriptase Increase both Drug Resistance and Viral Fitness in a Human Immunodeficiency Virus Type 1 Isolate Harboring the Multi-Nucleoside Reverse Transcriptase Inhibitor Resistance 69 Insertion Complex Mutation
  71. In Vitro Intersubtype Recombinants of Human Immunodeficiency Virus Type 1: Comparison to Recent and Circulating In Vivo Recombinant Forms
  72. Human Immunodeficiency Virus Type 1 (HIV-1)Quasispecies at the Sites of Mycobacterium tuberculosis InfectionContribute to Systemic HIV-1 Heterogeneity
  73. Mechanisms Involved in Stimulation of Human Immunodeficiency Virus Type 1 Replication by Aminooxypentane RANTES
  74. Functional Characterization of Chimeric Reverse Transcriptases with Polypeptide Subunits of Highly Divergent HIV-1 Group M and O Strains
  75. A Dual Infection/Competition Assay Shows a Correlation between Ex Vivo Human Immunodeficiency Virus Type 1 Fitness and Disease Progression
  76. Greater Diversity of HIV-1 Quasispecies in HIV-Infected Individuals With Active Tuberculosis
  77. Variable Sensitivity of CCR5-Tropic Human Immunodeficiency Virus Type 1 Isolates to Inhibition by RANTES Analogs
  78. Phylogeny of HIV Type 1 Group O Isolates Based on env Gene Sequences
  79. Molecular Epidemiology of HIV Type 1 Isolates from the Czech Republic: Identification of an env E Subtype Case
  80. Nucleotide Diversity in Three Different Genomic Regions of Venezuelan HIV Type 1 Isolates: A Subtyping Update
  81. Analysis of pol Gene Heterogeneity, Viral Quasispecies, and Drug Resistance in Individuals Infected with Group O Strains of Human Immunodeficiency Virus Type 1
  82. LTR and tat variability of HIV-1 isolates from patients with divergent rates of disease progression
  83. 3′-Azido-3′-Deoxythymidine (AZT) Mediates Cross-Resistance to Nucleoside Analogs in the Case of AZT-Resistant Human Immunodeficiency Virus Type 1 Variants
  84. Mechanisms of clinical resistance by HIV-I variants to zidovudine and the paradox of reverse transcriptase sensitivity
  85. Characterization of the Reverse Transcriptase of a Human Immunodeficiency Virus Type 1 Group O Isolate
  86. Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants
  87. Sequence Note : env Gene Characterization of the First HIV Type 1 Group O Spanish Isolate
  88. Point Mutant Frequencies in thepolGene of Human Immunodeficiency Virus Type 1 Are Two- to Threefold Lower Than Those ofenv
  89. Activation of antigen-induced lymphocyte proliferation by interleukin-15 without the mitogenic effect of interleukin-2 that may induce human immunodeficiency virus-1 expression.
  90. Sequence Note: env Gene Diversity of HIV Type 1 Isolates from Spain
  91. Molecular Characterization of Human Immunodeficiency Virus Type 1 Isolates from Venezuela
  92. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy
  93. Muscular Changes in Venezuelan Wild Horses Naturally Infected with Trypanosoma evansi
  94. Seroprevalence of retroviruses in the Amazonian rainforest